WSO - April 2023 - 406

406
International Journal of Stroke 18(4)
approach may result in an efficient and strategic utilization of
cardiac rhythm monitoring resources. This may avoid unnecessary
long-term monitoring and promote early PFO closure
in younger patients with a low likelihood of having AF, as
well as avoid PFO closure in older patients before a reasonable
confirmation of the absence of AF has been obtained.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: In the last 3 years, H.-C.D. received honoraria for contribution
to advisory boards or oral presentations from: Abbott, Actelion,
BMS, Boehringer Ingelheim, Daiichi Sankyo, Novo Nordisk, Pfizer,
and WebMD Global. Boehringer Ingelheim provided financial support
for research projects. In the last 3 years, R.W. received honoraria
for contribution to advisory boards or oral presentations from
AstraZeneca, Bayer, BMS, Boehringer Ingelheim, CVRx, Daiichi
Sankyo, Medtronic, Novartis, Pfizer, Pharmacosmos, Servier, and
SOBI. He received grant support from Bundesministerium für
Bildung und Forschung (BMBF), Deutsche Forschungsgemeinschaft,
European Union, and Medtronic. In the last 3 years, A.W. received
honoraria for contribution to advisory boards or oral presentations
from: Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer
Ingelheim, Eli Lilly, Gore Medical, Medtronic, and Pfizer. V.T.
reports personal compensation for consulting and speaking from
Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, Medtronic,
Abbott, Biotronik, Allergan, and Amgen. R.B.S. has received funding
from the European Research Council (ERC) under the European
Union's Horizon 2020 research and innovation program under the
grant agreement no. 648131, from the European Union's Horizon
2020 research and innovation program under the grant agreement
no. 847770 (AFFECT-EU), German Center for Cardiovascular
Research (DZHK e.V.) (81Z1710103), German Ministry of
Research and Education (BMBF 01ZX1408A), and ERACo
SysMed3 (031L0239). R.B.S. has received lecture fees and advisory
board fees from BMS/Pfizer outside this work. G.N. reports speaker
and/or consultancy fees and/or research support from Amgen, Bayer,
BMS/Pfizer, Boehringer Ingelheim, Elpen, Galenica, Sanofi, and
Winmedica, outside this work. S.K. has received grant support from
WL Gore, Bristol Myers Squibb, Bayer, Genentech, Medtronic; consulting
fees from Bristol Myers Squibb, Medtronic, AbbVie, and
Abbott; and royalties from UpToDate and Elsevier. In the last
3 years, P.M.R. received honoraria for contribution to advisory
boards or oral presentations from Abbott, Bayer, BMS, and Sanofi.
R.P. reports consulting fees from Medtronic, Abbott, and Janssen,
research support from Abbott, and royalties from UpToDate. J.L.S.
reports honoraria from Abbott, Boehringer Ingelheim, Bayer, BMS,
and Johnson and Johnson for service on clinical trial steering committees
advising on rigorous study design and conduct. B.A.A.
reports consultancy fees received from Abbott. R.A.B. reports personal
compensation for consulting and speaking from Astra Zeneca,
Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, AbbVie,
Medtronic, Abbott, and AMAG.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
Abbott provided funding for clinical consultancy.
International Journal of Stroke, 18(4)
ORCID iDs
Hans-Christoph Diener
8612
George Ntaios
https://orcid.org/0000-0002-6556https://orcid.org/0000-0002-0629-9248
Supplemental
material
Supplemental material for this article is available online.
References
1. Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen
ovale closure or antiplatelet therapy for cryptogenic stroke. N
Engl J Med 2017; 377: 1033-1042.
2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of
patent foramen ovale closure or medical therapy after stroke.
N Engl J Med 2017; 377: 1022-1032.
3. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale
closure or anticoagulation vs. antiplatelets after stroke. N Engl
J Med 2017; 377: 1011-1021.
4. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and highrisk
patent foramen ovale: the DEFENSE-PFO trial. J Am
Coll Cardiol 2018; 71: 2335-2342.
5. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical
therapy for cryptogenic stroke with patent foramen ovale. N
Engl J Med 2012; 366: 991-999.
6. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of
patent foramen ovale in cryptogenic embolism. N Engl J Med
2013; 368: 1083-1091.
7. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of
undetermined source: the case for a new clinical construct.
Lancet Neurol 2014; 13: 429-438.
8. Elgendy AY, Saver JL, Amin Z, et al. Proposal for updated
nomenclature and classification of potential causative mechanism
in patent foramen ovale-associated stroke. JAMA Neurol
2020; 77: 878-886.
9. Steffel J, Collins R, Antz M, et al. 2021 European Heart
Rhythm Association practical guide on the use of non-vitamin
K antagonist oral anticoagulants in patients with atrial fibrillation.
Europace 2021; 23: 1612-1676.
10. D'Andrea A, Dweck MR, Holte E, et al. EACVI survey on
the management of patients with patent foramen ovale and
cryptogenic stroke. Eur Heart J Cardiovasc Imaging 2021;
22: 135-141.
11. Horlick E, Kavinsky CJ, Amin Z, et al. SCAI expert consensus
statement on operator and institutional requirements for
PFO closure for secondary prevention of paradoxical embolic
stroke: the American Academy of Neurology affirms the
value of this statement as an educational tool for neurologists.
Catheter Cardiovasc Interv 2019; 93: 859-874.
12. Rubiera M, Aires A, Antonenko K, et al. European Stroke
Organisation (ESO) guideline on screening for subclinical
atrial fibrillation after stroke or transient ischaemic
attack of undetermined origin. Eur Stroke J 2022; 7:
CVII -CXXXIX.
13. Pristipino C, Sievert H, D'Ascenzo F, et al. European position
paper on the management of patients with patent foramen
ovale. General approach and left circulation thromboembolism.
EuroIntervention 2019; 14: 1389-1402.
14. Wein T, Lindsay MP, Côté R, et al. Canadian stroke best practice
recommendations: secondary prevention of stroke, sixth
https://www.orcid.org/0000-0002-6556-8612 https://www.orcid.org/0000-0002-6556-8612 https://www.orcid.org/0000-0002-0629-9248
WSO - April 2023

Table of Contents for the Digital Edition of WSO - April 2023
